Stock Track | Ligand Pharmaceuticals Soars 5.80% Intraday Following RBC Capital Price Target Hike

Stock Track05-09

Ligand Pharmaceuticals (LGND) stock soared 5.80% during intraday trading on Friday, reflecting strong positive momentum in the session.

The surge appears to be driven by bullish analyst actions from RBC Capital. The firm raised its price target on Ligand Pharmaceuticals to $262 from $252 while maintaining its Outperform rating. RBC also reiterated its Buy rating on the company with the same price target, signaling continued confidence in its prospects.

Positive analyst revisions often influence investor sentiment, and the significant increase in the price target likely contributed to the heightened buying activity and the stock's substantial intraday gain.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182360522?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-09 02:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182360522","market":"nz","top_or_hot":-1,"title":"Stock Track | Ligand Pharmaceuticals Soars 5.80% Intraday Following RBC Capital Price Target Hike","media":"Stock Track","content":"<p>Ligand Pharmaceuticals (LGND) stock soared 5.80% during intraday trading on Friday, reflecting strong positive momentum in the session.</p><p>The surge appears to be driven by bullish analyst actions from RBC Capital. The firm raised its price target on Ligand Pharmaceuticals to $262 from $252 while maintaining its Outperform rating. RBC also reiterated its Buy rating on the company with the same price target, signaling continued confidence in its prospects.</p><p>Positive analyst revisions often influence investor sentiment, and the significant increase in the price target likely contributed to the heightened buying activity and the stock's substantial intraday gain.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ligand Pharmaceuticals Soars 5.80% Intraday Following RBC Capital Price Target Hike</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ligand Pharmaceuticals Soars 5.80% Intraday Following RBC Capital Price Target Hike\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-09 02:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ligand Pharmaceuticals (LGND) stock soared 5.80% during intraday trading on Friday, reflecting strong positive momentum in the session.</p><p>The surge appears to be driven by bullish analyst actions from RBC Capital. The firm raised its price target on Ligand Pharmaceuticals to $262 from $252 while maintaining its Outperform rating. RBC also reiterated its Buy rating on the company with the same price target, signaling continued confidence in its prospects.</p><p>Positive analyst revisions often influence investor sentiment, and the significant increase in the price target likely contributed to the heightened buying activity and the stock's substantial intraday gain.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LGND","symbol_name":"Ligand Pharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1182360522","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182360522","pubTimestamp":1778264470,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ligand Pharmaceuticals (LGND) stock soared 5.80% during intraday trading on Friday, reflecting strong positive momentum in the session.The surge appears to be driven by bullish analyst actions from...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LGND":"Ligand Pharmaceuticals Inc."},"translate_title":"个股追踪|RBC Capital上调目标价后Ligand Pharmaceuticals盘中大涨5.80%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGND":1},"content_text":"Ligand Pharmaceuticals (LGND) stock soared 5.80% during intraday trading on Friday, reflecting strong positive momentum in the session.The surge appears to be driven by bullish analyst actions from RBC Capital. The firm raised its price target on Ligand Pharmaceuticals to $262 from $252 while maintaining its Outperform rating. RBC also reiterated its Buy rating on the company with the same price target, signaling continued confidence in its prospects.Positive analyst revisions often influence investor sentiment, and the significant increase in the price target likely contributed to the heightened buying activity and the stock's substantial intraday gain.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182360522","isCrawlerRequest":true}